Paolo A. Muraro

Room E415, 160 Du Cane Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Should autologous HSCT be a first-line option in highly active MS: YES.

Should autologous HSCT be a first-line option in highly active MS: YES.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 26, 2026

A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosis.

A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosis.

Journal: Brain : a journal of neurology

Published: January 30, 2026

Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.

Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 07, 2025

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party.

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party.

Journal: Bone marrow transplantation

Published: May 19, 2025

Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK.

Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 14, 2025

Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.

Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.

Journal: Multiple sclerosis and related disorders

Published: March 24, 2025

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT).

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT).

Journal: British journal of haematology

Published: February 24, 2025

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.

Journal: Nature reviews. Neurology

Published: December 11, 2024

Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.

Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.

Journal: Practical neurology

Published: October 01, 2024

Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis.

Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis.

Journal: Handbook of clinical neurology

Published: August 07, 2024

Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.

Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.

Journal: Annals of neurology

Published: July 15, 2024

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.

Journal: BMJ open

Published: February 05, 2024

Showing 1-12 of 89

Last Updated: 09/26/2026